• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Bridges and Landmarks Across the USA Will Illuminate Blue Throughout the Month of September for Alopecia Areata

    9/1/22 7:00:00 AM ET
    $CNCE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CNCE alert in real time by email

    September is Alopecia Areata Awareness Month

    Alopecia Areata is a Serious Autoimmune Disorder with Limited Treatment Options

    In recognition of Alopecia Areata Awareness Month, bridges, buildings and other landmarks across the United States will be illuminated blue to raise awareness for this serious autoimmune disease.

    The effort will unite U.S. cities in observance of Alopecia Areata Awareness Month, which is recognized annually during September. The current illumination schedule follows below. Any updates or additions to the schedule will be posted here. If you plan to visit an illumination, we invite you to take a photo and tag your social media postings with the hashtag: #LightItUpBlue4AlopeciaAreata.

    • September 1: McNichols Civic Center – Denver, Colorado
    • September 1: Seattle Convention Center – Seattle, Washington
    • September 1-30: Hoover City Hall – Hoover, Alabama
    • September 2: 230 Park Avenue (The Helmsley Building) – New York, New York
    • September 2: Niagara Falls – Niagara Falls, NY and Ontario, Canada, 10:00 -10:15 p.m. ET
    • September 3: Murray Baker Bridge – Peoria, Illinois
    • September 3-4: Helix Garage – Lexington, Kentucky
    • September 4: Peace Bridge – Buffalo, New York
    • September 4: Woodburn Bridge – Woodburn, Oregon
    • September 6: Leonard P. Zakim Bunker Hill Memorial Bridge – Boston, Massachusetts
    • September 6: Longfellow Bridge – Boston, Massachusetts
    • September 6: Fore River Bridge – Quincy, Massachusetts
    • September 6: Kenneth F. Burns Memorial Bridge – Worcester, Massachusetts
    • September 6: Nasdaq Tower Times Square – New York, New York
    • September 6: Pennsylvania State Capitol – Harrisburg, Pennsylvania
    • September 7: Memorial Bridge – Kittery, Maine
    • September 7-21: Milwaukee County Historical Society – Milwaukee, Wisconsin
    • September 8: Caesars Superdome – New Orleans, Louisiana
    • September 8: Tennessee State Capitol – Nashville, Tennessee
    • September 8-9: NASCAR Hall of Fame – Charlotte, North Carolina
    • September 8-17: JUMP - Jack's Urban Meeting Place – Boise, Idaho
    • September 9-12: Concord Hotel – Concord, New Hampshire
    • September 9: Waterbury City Hall and Chase Building – Waterbury, Connecticut
    • September 9: Sakonnet River Bridge – Tiverton, Rhode Island
    • September 10: Union Plaza Building – Little Rock, Arkansas
    • September 10: DoubleTree by Hilton Hotel – Albuquerque, New Mexico
    • September 10-11: Strollway Pedestrian Bridge – Winston-Salem, North Carolina
    • September 10-11: Green Street Pedestrian Bridge – Winston-Salem, North Carolina
    • September 10-11: Twin Arches – Winston-Salem, North Carolina
    • September 12: Las Vegas City Hall – Las Vegas, Nevada
    • September 12: Davenport Skybridge – Davenport, Iowa
    • September 12: Sperry Tower – Eagen, Minnesota
    • September 13: Marian H. Rochelle Gateway Center – Laramie, Wyoming
    • September 14: Skydance Bridge – Oklahoma City, Oklahoma
    • September 14: Pacifica Honolulu – Honolulu, Hawaii
    • September 15: Governor Mario M. Cuomo Bridge – Tarrytown, New York
    • September 15: Barclay Damon Tower – Syracuse, New York
    • September 15: Union Street Railroad Bridge – Salem, Oregon
    • September 16: US17 Bridge – Charleston, South Carolina
    • September 16-18: Legislative Hall: Delaware State Capitol – Dover, Delaware
    • September 17: ARCH/Historic 10th Street Bridge – Great Falls, Montana
    • September 18: JL Tower – Anchorage, Alaska
    • September 19: Fargo City Hall – Fargo, North Dakota
    • September 19: Franklin D. Roosevelt Mid-Hudson Bridge – Poughkeepsie, New York
    • September 19: RSA Bank Trust Building – Mobile, Alabama
    • September 19: RSA Van Antwerp Building – Mobile, Alabama
    • September 19: RSA Tower Building – Montgomery Alabama
    • September 19: RSA Judicial Building – Montgomery, Alabama
    • September 19: Renaissance Montgomery Hotel & Spa and Convention Center – Montgomery, Alabama
    • September 20: Wells Fargo's Duke Energy Center – Charlotte, North Carolina
    • September 20: Bakowski Bridge of Lights – Shreveport, Louisiana
    • September 21: The Wheel at Icon Park – Orlando, Florida
    • September 22: Nasdaq Tower Times Square – New York, New York
    • September 22: Pawtucket River Bridge – Pawtucket, Rhode Island
    • September 23: France Avenue Lights – Edina, Minnesota
    • September 23-25: Concourse Office Park (King and Queen Buildings) – Atlanta, Georgia
    • September 24: Bank of America Plaza – Dallas, Texas
    • September 24: Elk River Bridge – Charleston, West Virginia
    • September 25: Museum at Prairiefire – Overland Park, Kansas
    • September 25: Cleveland Terminal Tower – Cleveland, Ohio
    • September 26: City of Moreno Valley "M" – Moreno Valley, California
    • September 26-28: Gilbert Water Tower – Gilbert, Arizona
    • September 27: Main Street Square Spires – Rapid City, South Dakota
    • September 27-30: Blue Bridge – Grand Rapids, Michigan
    • September 28: River Lights in the Rock, Main Street Junction and Clinton Park Bridges – Little Rock, Arkansas
    • September 28: Old Vanderburgh County Courthouse – Evansville, Indiana
    • September 28: One Liberty Place – Philadelphia, Pennsylvania
    • September 29: Bob Kerrey Pedestrian Bridge – Omaha, Nebraska
    • September 30: Kansas City Power and Light Building – Kansas City, Missouri
    • September 30: Bridge of Lights – Ocean City, New Jersey
    • September 30: Virginia Aquarium & Marine Science Center – Virginia Beach, Virginia

    In some instances, a live cam may be available to view the illumination from home. For example, Niagara Falls provides a live cam here, and the Mario M. Cuomo Bridge, here. Is there a landmark near you? Help us light up the night sky by reaching out to local landmarks to request a blue illumination for Alopecia Areata Awareness Month, then post a photo with #LightItUpBlue4AlopeciaAreata.

    Other Ways to Get Involved

    Anyone can join the campaign from the comfort of their own home by changing the light on their porch or in a favorite lamp to blue and taking a selfie with the light to share on social media. Inexpensive blue bulbs are available at local lighting and home improvement stores or online. Be sure to tag #LightItUpBlue4AlopeciaAreata in social media posts.

    Special Thanks

    On behalf of the alopecia areata community, special thanks to the patient advocacy groups who provide important resources all year long: Bald Girls Do Lunch, National Alopecia Areata Foundation (NAAF), Canadian Alopecia Areata Foundation (CANAAF), Alopecia UK and This Is Me Foundation.

    Thank you also to all the landmarks coast to coast for recognizing the importance of Alopecia Areata Awareness Month by lighting it up blue for alopecia areata, and to the photographers who shared their images to help raise awareness.

    About Alopecia Areata

    Alopecia areata is a common autoimmune skin disease that causes hair loss on the scalp, face and sometimes other areas of the body.

    Alopecia areata may affect up to approximately 1.5 million Americans at any given time. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. Onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently limited treatment options available for alopecia areata.

    The Light It Up Blue 4 Alopecia Areata campaign is made possible by Concert Pharmaceuticals, Inc.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005178/en/

    Get the next $CNCE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CNCE

    DatePrice TargetRatingAnalyst
    10/5/2021$13.00 → $9.00Buy
    Mizuho
    More analyst ratings

    $CNCE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata

      Concert Pharmaceuticals, Inc. today announced that, after a recent review of deuruxolitinib clinical data by the U.S. Food and Drug Administration (FDA), the FDA determined that deuruxolitinib will maintain its Breakthrough Therapy designation. Deuruxolitinib, an oral Janus kinase (JAK) inhibitor, is being developed for the treatment of adult patients with moderate to severe alopecia areata. In light of the FDA approval of a different JAK inhibitor as the first treatment for alopecia areata, the FDA previously notified Concert that it was reviewing the Breakthrough Therapy designation previously granted for deuruxolitinib. At the FDA's request, Concert submitted additional clinical data an

      2/15/23 7:00:00 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

      Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma's Global Dermatology Franchise by Adding a Late-Stage Product in an Area with Significant Unmet Need Sun Pharma to Commence Tender Offer to Acquire All Outstanding Shares of Common Stock of Concert Upfront Cash Payment of $8.00 per Share of Common Stock, or Equity Consideration of $576 Million, and Contingent Value Right for up to $3.50 per Share of Common Stock on Achievement of Certain Time-Based Net Sales M

      1/19/23 9:39:00 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

      Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma's Global Dermatology Franchise by Adding a Late-Stage Product in an Area with Significant Unmet Need Sun Pharma to Commence Tender Offer to Acquire All Outstanding Shares of Common Stock of Concert Upfront Cash Payment of $8.00 per Share of Common Stock, or Equity Consideration of $576 Million, and Contingent Value Right for up to $3.50 per Share of Common Stock on Achievement of Certain Time-Based Net Sale

      1/19/23 8:00:00 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNCE
    Leadership Updates

    Live Leadership Updates

    See more
    • KalVista Pharmaceuticals Appoints Nancy Stuart to Board of Directors

      CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Nancy Stuart has been appointed to its Board of Directors effective March 18, 2021. Ms. Stuart is Chief Operating Officer at Concert Pharmaceuticals Inc. (NASDAQ: CNCE) and is a leader in strategic planning, business operations and business development in the biopharmaceutical and biotechnology industries. “We are pleased to welcome Nancy to our Board of Directors. Her experience at a broad range of companies from both a

      3/19/21 7:00:00 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNCE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Stuart Nancy sold $50,380 worth of shares (6,048 units at $8.33) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 262,596 units (withholding obligation)

      4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)

      2/16/23 8:51:22 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Munsie Jeffrey A sold $31,375 worth of shares (3,762 units at $8.34) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 88,049 units to cover withholding tax

      4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)

      2/16/23 8:49:56 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Cassella James V sold $31,375 worth of shares (3,762 units at $8.34) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 173,061 units to satisfy withholding obligation

      4 - CONCERT PHARMACEUTICALS, INC. (0001367920) (Issuer)

      2/16/23 8:48:59 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNCE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Concert Pharmaceuticals Inc. (Amendment)

      SC 13G/A - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)

      2/14/23 4:45:50 PM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Concert Pharmaceuticals Inc. (Amendment)

      SC 13G/A - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)

      2/14/23 2:35:53 PM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Concert Pharmaceuticals Inc.

      SC 13G - CONCERT PHARMACEUTICALS, INC. (0001367920) (Subject)

      2/13/23 9:25:22 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNCE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho reiterated coverage on Concert Pharmaceuticals with a new price target

      Mizuho reiterated coverage of Concert Pharmaceuticals with a rating of Buy and set a new price target of $9.00 from $13.00 previously

      10/5/21 7:29:28 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Truist reiterated coverage on Concert Pharmaceuticals with a new price target

      Truist reiterated coverage of Concert Pharmaceuticals with a rating of and set a new price target of $22.00 from $30.00 previously

      2/2/21 11:37:54 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Truist Securities reiterated coverage on Concert Pharmaceuticals with a new price target

      Truist Securities reiterated coverage of Concert Pharmaceuticals with a rating of Buy and set a new price target of $22.00 from $30.00 previously

      2/2/21 11:13:03 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNCE
    Financials

    Live finance-specific insights

    See more
    • Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

      Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma's Global Dermatology Franchise by Adding a Late-Stage Product in an Area with Significant Unmet Need Sun Pharma to Commence Tender Offer to Acquire All Outstanding Shares of Common Stock of Concert Upfront Cash Payment of $8.00 per Share of Common Stock, or Equity Consideration of $576 Million, and Contingent Value Right for up to $3.50 per Share of Common Stock on Achievement of Certain Time-Based Net Sales M

      1/19/23 9:39:00 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

      Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharma's Global Dermatology Franchise by Adding a Late-Stage Product in an Area with Significant Unmet Need Sun Pharma to Commence Tender Offer to Acquire All Outstanding Shares of Common Stock of Concert Upfront Cash Payment of $8.00 per Share of Common Stock, or Equity Consideration of $576 Million, and Contingent Value Right for up to $3.50 per Share of Common Stock on Achievement of Certain Time-Based Net Sale

      1/19/23 8:00:00 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Concert Pharmaceuticals Reports Third Quarter 2022 Financial Results

      Company Plans to Submit NDA in First Half of 2023 for Deuruxolitinib in Adults with Moderate to Severe Alopecia Areata Deuruxolitinib (CTP-543) Phase 3 Data Presented at the EADV Congress Late Breaking News Session Additional Deuruxolitinib Phase 3 Results to be Presented at the World Congress for Hair Research Conference Call Scheduled Today at 8:30 a.m. ET; Registration Required to Join Live Call Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today reported financial results for the third quarter of 2022. "With the THRIVE-AA clinical program completed and positive Phase 3 results in hand for deuruxolitinib in alopecia areata, we are well on our way to meeting our goal of submitting the

      11/7/22 7:00:00 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNCE
    SEC Filings

    See more
    • SEC Form 15-12G filed by Concert Pharmaceuticals Inc.

      15-12G - CONCERT PHARMACEUTICALS, INC. (0001367920) (Filer)

      3/16/23 9:00:55 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Concert Pharmaceuticals Inc.

      EFFECT - CONCERT PHARMACEUTICALS, INC. (0001367920) (Filer)

      3/14/23 12:15:21 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Concert Pharmaceuticals Inc.

      EFFECT - CONCERT PHARMACEUTICALS, INC. (0001367920) (Filer)

      3/14/23 12:15:15 AM ET
      $CNCE
      Biotechnology: Pharmaceutical Preparations
      Health Care